Image source: Shutterstock

Highlights

  • In FY24, CSL achieved an 11% YoY revenue growth, reaching USD 14.8 billion, with NPAT surging 20% YoY to USD 2.64 billion.
  • CSL Behring continues to see rising demand for immunoglobulin (Ig) therapies across core indications.
  • CSL projects 5-7% revenue growth and 10-13% earnings growth in FY25.

CSL Limited (ASX:CSL) is an ASX-listed global biopharmaceutical company. The company achieved an 11% YoY jump in its total revenue in the fiscal year ended 30 June 2024 (FY24), reaching USD 14.8 billion. Net Profit After Tax (NPAT) during the year surged by 20% YoY to USD 2.64 billion, while operating cash flow increased by 6% YoY to USD 2.76 billion.

The growth was primarily driven by CSL Behring, which experienced increasing patient demand and a recovery in gross margins. Additionally, CSL Seqirus surpassed market expectations, largely due to the strong performance of its adjuvanted influenza vaccine, FLUAD®.

Segment wise outlook

CSL Behring - CSL Behring continues to see rising demand for immunoglobulin (Ig) therapies across core indications. The positive uptake of HEMGENIX with favourable reimbursement approvals has further strengthened CSL Behring’s market position. Additionally, regulatory approval is anticipated for GARADACIMAB and the deployment of Rika technology are expected to enhance gross margin.

CSL Seqirus - CSL Seqirus has continued to outperform market, supported by its differentiated product portfolio. The company is preparing for the commercial launch of KOSTAIVE in Japan, with regulatory approvals in progress for the EU and US markets. Additionally, CSL Seqirus is actively working on potential avian flu vaccines.

CSL Vifor - CSL Vifor is prioritising growth in the nephrology sector, focusing on advancing its Patient Blood Management program in collaboration with CSL Behring.

Outlook for FY25

CSL has reaffirmed its FY25 financial guidance, forecasting revenue growth of 5-7% at constant currency. The company anticipates NPATA to range between USD 3.2-3.3 billion, reflecting an annual earnings growth of 10-13%.

CSL expects to maintain its double-digit earnings growth trajectory over the medium term.

Share performance of CSL

CSL shares closed 0.18% higher at AUD 270.34 per share on 10 February 2025. Over the past year, CSL’s share price has dropped by almost 11.36% and in the last three months, it has declined by 5.91%.

52-week high of CSL is AUD 313.55, recorded on 24 July 2024 and 52-week low is AUD 265.14, recorded on 19 April 2024.

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 10 February 2025. The reference data in this report has been partly sourced from EODHD/Others.